The Corticotropin Releasing Hormone-1 (CRH1) Receptor Antagonist Pexacerfont in Alcohol Dependence: A Randomized Controlled Experimental Medicine Study

Neuropsychopharmacology

Volumn 40, Issue , 2015, Pages 1053-1063

  Kwako, Laura E ^a   Spagnolo, Primavera A ^a   Schwandt, Melanie L ^a   Thorsell, Annika ^a,b   George, David T ^a   Momenan, Reza ^a   Rio, Daniel E ^a   Huestis, Marilyn ^c   Anizan, Sebastien ^c   Concheiro, Marta ^c   Sinha, Rajita ^d   Heilig, Markus ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^b LINKÖPING UNIVERSITY   (Sweden)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEXACERFONT; CORTICOTROPIN; HYDROCORTISONE; PLACEBO; ALCOHOL; CENTRAL DEPRESSANT AGENT; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; DRUGS USED IN THE TREATMENT OF ADDICTION; PYRAZOLE DERIVATIVE; TRIAZINE DERIVATIVE;

ADDICTION SEVERITY INDEX; ADULT; ALCOHOLISM; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GUIDED IMAGERY; HEALTH CARE QUALITY; HUMAN; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; NERVE POTENTIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR OCCUPANCY; SOFT DRINK; STATE TRAIT ANXIETY INVENTORY; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; TREATMENT DURATION; TREATMENT WITHDRAWAL; VISUAL ANALOG SCALE; ALCOHOL WITHDRAWAL; CENTRAL NERVOUS SYSTEM; DISSOCIATION; DISTRESS SYNDROME; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EXPOSURE; NEUROIMAGING; PSYCHOPHARMACOTHERAPY; STEADY STATE; AGED; ANTAGONISTS AND INHIBITORS; ASSOCIATION; BRAIN; CRAVING; DRUG EFFECTS; EMOTION; MENTAL STRESS; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY; VISION; YOUNG ADULT;

ADULT; AGED; ALCOHOL DETERRENTS; ALCOHOLISM; BRAIN; CENTRAL NERVOUS SYSTEM DEPRESSANTS; CRAVING; CUES; DOUBLE-BLIND METHOD; EMOTIONS; ETHANOL; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PYRAZOLES; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; STRESS, PSYCHOLOGICAL; TRIAZINES; VISUAL PERCEPTION; YOUNG ADULT;

EID: 84925514304     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2014.306     Document Type: Article

References (55)

1. Bernstein DP, Fink L, Handelsman L, Foote J, Lovejoy M, Wenzel K et al (1994). Initial reliability and validity of a new retrospective measure of child abuse and neglect. A J Psychiatry 151: 1132-1136.
2. Binneman B, Feltner D, Kolluri S, Shi Y, Qiu R, Stiger T (2008). A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. AJ Psychiatry 165: 617-620.
3. Bohn MJ, Krahn DD, Staehler BA (1995). Development and initial validation of a measure of drinking urges in abstinent alcoholics. Alcohol Clin Exp Res 19: 600-606.
4. Bossert JM, Marchant NJ, Calu DJ, Shaham Y (2013). The reinstatement model of drug relapse: recent neurobiological findings, emerging research topics, and translational research. Psychopharmacology (Berl) 229: 453-476.
5. Brownell KD, Marlatt GA, Lichtenstein E, Wilson GT (1986). Understanding and preventing relapse. Am Psychol 41: 765-782.
6. Coric V, Feldman HH, Oren DA, Shekhar A, Pultz J, Dockens RC et al (2010). Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropinreleasing factor receptor-1 antagonist in generalized anxiety disorder. Depress Anxiety 27: 417-425.
7. Costa PTM, R. R (2002). NEO Personality Inventory-Revised (NEO PI-R). APA: Washington, DC, USA.
8. Cox RW (1996). AFNI: Software for analysis and visualization of functional magnetic resonance neuroimages. Comput Biomed Res 29: 162-173.
9. Epstein DH, Preston KL, Stewart J, Shaham Y (2006). Toward a model of drug relapse: an assessment of the validity of the reinstatement procedure. Psychopharmacology (Berl) 189: 1-16.
10. First MB, Spitzer RL, Gibbon M, Williams JBW (1996). Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV) . American Psychiatric Press, Inc.: Washington, DC, USA.
11. Foa EB, Riggs DS, Dancu CV, Rothbaum BO (1993). Reliability and validity of a brief instrument for assessing posttraumatic-stress-disorder. J Trauma Stress 6: 459-473.
12. Fox HC, Anderson GM, Tuit K, Hansen J, Kimmerling A, Siedlarz KM et al (2012). Prazosin effects on stress- and cue-induced craving and stress response in alcohol-dependent individuals: preliminary findings. Alcohol Clin Exp Res 36: 351-360.
13. Funk CK, O'Dell LE, Crawford EF, Koob GF (2006). Corticotropin-releasing factor within the central nucleus of the amygdala mediates enhanced ethanol self-administration in withdrawn, ethanol-dependent rats. J Neurosci 26: 11324-11332.
14. Funk CK, Zorrilla EP, Lee MJ, Rice KC, Koob GF (2007). Corticotropin-releasing factor 1 antagonists selectively reduce ethanol self-administration in ethanol-dependent rats. Biol Psychiatry 61: 78-86.
15. Gehlert DR, Cippitelli A, Thorsell A, Le AD, Hipskind PA, Hamdouchi C et al (2007). 3-(4-Chloro-2-morpholin-4-yl-thiazol- 5-yl)-8-(1-ethylpropyl)-2,6-dimethyl-imidazo [1,2-b]pyridazine: a novel brain-penetrant, orally available corticotropinreleasing factor receptor 1 antagonist with efficacy in animal models of alcoholism. J Neurosci 27: 2718-2726.
16. George DT, Gilman J, Hersh J, Thorsell A, Herion D, Geyer C et al (2008). Neurokinin 1 receptor antagonism as a possible therapy for alcoholism. Science 319: 1536-1539.
17. Gilligan PJ, Baldauf C, Cocuzza A, Chidester D, Zaczek R, Fitzgerald LW et al (2000). The discovery of 4-(3-pentylami-no)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine: a corticotropin-releasing factor (hCRF1) antagonist. Bioorg Med Chem 8: 181-189.
18. Gilligan PJ, Clarke T, He L, Lelas S, Li YW, Heman K et al (2009). Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists. J Med Chem 52: 3084-3092.
19. Heilig M, Egli M (2006). Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol Ther 111: 855-876.
20. Heilig M, Egli M, Crabbe JC, Becker HC (2010). Acute withdrawal, protracted abstinence and negative affect in alcoholism: are they linked? Addict Biol 15: 169-184.
21. Heilig M, Goldman D, Berrettini W, O'Brien CP (2011). Pharmacogenetic approaches to the treatment of alcohol addiction. Nat Rev Neurosci 12: 670-684.
22. Heilig M, Koob GF (2007). A key role for corticotropinreleasing factor in alcohol dependence. Trends Neurosci 30: 399-406.
23. Ipser JC, Stein DJ (2012). Evidence-based pharmacotherapy of post-traumatic stress disorder (PTSD). Int J Neuropsychopharmacol 15: 825-840.
24. Kenward MG, Roger JH (1997). Small sample inference for fixed effects from restricted maximum likelihood. Biometrics 53: 983-997.
25. Kirschbaum C, Pirke KM, Hellhammer DH (1993). The 'Trier Social Stress Test'-a tool for investigating psychobiological stress responses in a laboratory setting. Neuropsychobiology 28: 76-81.
26. Kwako LE, Schwandt ML, Sells JR, Ramchandani VA, Hommer DW, George DT et al (2014). Methods for inducing alcohol craving in individuals with co-morbid alcohol dependence and posttraumatic stress disorder: behavioral and physiological outcomes. Addict Biol; e-pub ahead of print.
27. Lang PJ, Bradley MM, Cuthbert BN (1999). International Affective Picture System (IAPS): Technical Manual and Affective Ratings. The Center for Research in Psychophysiology, University of Florida: Gainesville, FL, USA.
28. Le AD, Funk D, Coen K, Li Z, Shaham Y (2013). Role of corticotropin-releasing factor in the median raphe nucleus in yohimbine-induced reinstatement of alcohol seeking in rats. Addict Biol 18: 448-451.
29. Le AD, Harding S, Juzytsch W, Fletcher PJ, Shaham Y (2002). The role of corticotropin-releasing factor in the median raphe nucleus in relapse to alcohol. J Neurosci 22: 7844-7849.
30. Le AD, Harding S, Juzytsch W, Watchus J, Shalev U, Shaham Y (2000). The role of corticotrophin-releasing factor in stress-induced relapse to alcohol-seeking behavior in rats. Psychopharmacology (Berl) 150: 317-324.
31. Le AD, Poulos CX, Harding S, Watchus J, Juzytsch W, Shaham Y (1999). Effects of naltrexone and fluoxetine on alcohol self-administration and reinstatement of alcohol seeking induced by priming injections of alcohol and exposure to stress. Neuropsychopharmacology 21: 435-444.
32. Littell RC (2006). SAS. Encyclopedia of Environmetrics . John Wiley & Sons, Ltd.
33. Liu X, Weiss F (2002). Additive effect of stress and drug cues on reinstatement of ethanol seeking: exacerbation by history of dependence and role of concurrent activation of corticotropinreleasing factor and opioid mechanisms. J Neurosci 22: 7856-7861.
34. Mann RE, Sobell LC, Sobell MB, Pavan D (1985). Reliability of a family tree questionnaire for assessing family history of alcohol problems. Drug Alcohol Depend 15: 61-67.
35. Marinelli PW, Funk D, Juzytsch W, Harding S, Rice KC, Shaham Y et al (2007). The CRF1 receptor antagonist antalarmin attenuates yohimbine-induced increases in operant alcohol self-administration and reinstatement of alcohol seeking in rats. Psychopharmacology (Berl) 195: 345-355.
36. Mason BJ, Light JM, Williams LD, Drobes DJ (2009). Proof-ofconcept human laboratory study for protracted abstinence in alcohol dependence: effects of gabapentin. Addict Biol 14: 73-83.
37. Mason BJ, Quello S, Goodell V, Shadan F, Kyle M, Begovic A (2014). Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Intern Med 174: 70-77.
38. Matsumoto D, Ekman P (1988). Japanese and Caucasian facial expressions of emotion and neutral faces (JACFEE and JACNeuF)Human Interaction Laboratory, University of California: San Francisco, CA, USA401.
39. McLellan AT, Luborsky L, Woody GE, O'Brien CP (1980). An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. J Nerv Ment Dis 168: 26-33.
40. O'Malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek MJ (2002). Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamopituitary-adrenocortical axis. Psychopharmacology (Berl) 160: 19-29.
41. Rydmark I, Wahlberg K, Ghatan PH, Modell S, Nygren A, Ingvar M et al (2006). Neuroendocrine, cognitive and structural imaging characteristics of women on longterm sickleave with job stress-induced depression. Biol Psychiatry 60: 867-873.
42. Sinha R (2009). Modeling stress and drug craving in the laboratory: implications for addiction treatment development. Addict Biol 14: 84-98.
43. Sinha R, Fox HC, Hong KA, Bergquist K, Bhagwagar Z, Siedlarz KM (2009). Enhanced negative emotion and alcohol craving, and altered physiological responses following stress and cue exposure in alcohol dependent individuals. Neuropsychopharmacology 34: 1198-1208.
44. Sinha R, Fox HC, Hong KI, Hansen J, Tuit K, Kreek MJ (2011). Effects of adrenal sensitivity, stress- and cue-induced craving, and anxiety on subsequent alcohol relapse and treatment outcomes. Arch Gen Psychiatry 68: 942-952.
45. Skinner HA (1984). Assessing alcohol-use by patients in treatment. Res Adv Alcohol Drug 8: 183-207.
46. Sobell MB, Sobell LC, Klajner F, Pavan D, Basian E (1986). The reliability of a timeline method for assessing normal drinker college students' recent drinking history: utility for alcohol research. Addict Behav 11: 149-161.
47. Sommer WH, Rimondini R, Hansson AC, Hipskind PA, Gehlert DR, Barr CS et al (2008). Upregulation of voluntary alcohol intake, behavioral sensitivity to stress, and amygdala crhr1 expression following a history of dependence. Biol Psychiatry 63: 139-145.
48. Spielberger CD, Gorsuch RL, Lushene RE (1970). STAI manual for the Stait-Trait Anxiety Inventory ('self-evaluation questionnaire'). Consulting Psychologists Press: Pal'o Alto, CA, USA, 24 p. pp.
49. Stasiewicz PR, Gulliver SB, Bradizza CM, Rohsenow DJ, Torrisi R, Monti PM (1997). Exposure to negative emotional cues and alcohol cue reactivity with alcoholics: a preliminary investigation. Behav Res Ther 35: 1143-1149.
50. Valdez GR, Zorrilla EP, Roberts AJ, Koob GF (2003). Antagonism of corticotropin-releasing factor attenuates the enhanced responsiveness to stress observed during protracted ethanol abstinence. Alcohol 29: 55-60.
51. Wolpe J (1969). The practice of behavior therapy. 1st edn. Pergamon Press: New York, 314 p. pp.
52. Zhou L, Dockens RC, Liu-Kreyche P, Grossman SJ, Iyer RA (2012). In vitro and in vivo metabolism and pharmacokinetics of BMS-562086, a potent and orally bioavailable corticotropinreleasing factor-1 receptor antagonist. Drug Metab Dispos 40: 1093-1103.
53. Zobel AW, Nickel T, Kunzel HE, Ackl N, Sonntag A, Ising M et al (2000). Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 34: 171-181.
54. Zorrilla EP, Heilig M, de Wit H, Shaham Y (2013). Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism. Drug Alcohol Depend 128: 175-186.
55. Zorrilla EP, Valdez GR, Nozulak J, Koob GF, Markou A (2002). Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat. Brain Res 952: 188-199.